GlaxoSmithKline PLC (GSK)

20.65
+0.97(+4.93%)
  • Volume:
    18,359
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    19.98 - 20.90
  • Type:Equity
  • Market:Germany
  • ISIN:GB0009252882
  • WKN:940561

GSK Overview

Prev. Close
19.68
Day's Range
19.98-20.9
Revenue
-
Open
19.98
52 wk Range
13.94-20.9
EPS
-
Volume
18,359
Market Cap
102.92B
Dividend (Yield)
80.00
(5.07%)
Average Vol. (3m)
4,216
P/E Ratio
19.57
Beta
-
1-Year Change
23.15%
Shares Outstanding
5,031,809,109
Next Earnings Date
-
What is your sentiment on GlaxoSmithKline PLC?
or
Vote to see community's results!

GlaxoSmithKline PLC Company Profile

Employees
94066

GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
  • 1st malaria vaccine approved by WHO. hopefully good news for the stock. definitely good for the developing world!
    1
    • Been In GSK since February and wearing almost a 15% gain which i'm pretty chuffed about , not sure what you guys think about GSK going into the future but i'm pretty happy with these returns and am thinking about investing in a PRE IPO called SpectrumX which i have seen on the homepage of LSE and the Sunday times. SpectrumXare leaders in proprietary formulations of HOCL, so looks promising for the future of pharmaceuticals. Have not dabbled with Pre IPOS so wanted to see what you guys think?
      1
      • to the moon!
        0
        • when?!
          0
        • Already mooned now buy back at 1300
          0
      • Good old GSK. Never fails to disappoint.
        0
        • AMAZING....great news, good earnings...it comes +2% to -0.7%....I`m done, I`m out
          0
        • As i said before this company does not understand competitive performance - radical change needed - one off hitting earnings forecast does not mean anything
          0
      • setting my buys at 12.5
        0
        • GSK will invent the vaccine of immortality
          0
          • Will not deliver on results - never does actually - the plans are all nice on paper - but its all just a financial excercise - the forecasts especially on oncology but not only are not real
            0
            • glx is about to split of the consumer division .
              0
              • Stock's been on fire these past 2 days. What's the driver?
                0
                • Anticipation that the briefing on the proposed split on 25 June will suggest an unlocking of value. GSK is a lame duck in the Covid race and in many other aspects, so also hope that the breakup will trigger bids for the separate businesses.
                  0
              • Best drug company there is.
                2
                • shall go over 15 before 23 June
                  0
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.